Health Canada
Symbol of the Government of Canada

Common menu bar links

About Health Canada

Access to Information Requests Completed - April 2014

The following is a list of Access to Information requests processed by Health Canada. The list is not all-inclusive. The list contains requests completed for which documents have been retrieved or treated. The list is provided in chronological order, by month and year, and by request number. (Requests focusing on personal information or third party proprietary information are not included.)

If you wish to obtain a copy of the records released in response to these requests informally, you may contact the Access to Information and Privacy Division.

For the Month of April 2014
Request # Summary of Requests Status of Completed Request Number of Pages Disclosed
A-2010-01040
  • Adverse reaction (AR) reports associated with Hydroxycut products in Canada;
  • Health Canada's (HC) notes about the product formulas, ingredients, dosages, or other causes which may pose a risk to health;
  • Correspondence between the Food and Drug D Administration (FDA) and HC;
  • Information that was used in deciding to recall and issue public health warnings
Disclosed in part 505
A-2011-01500 The summary of specific investigations undertaken or completed of illegal importation/use of pesticides that affect Canada's health, environment, waterways, agriculture and fish habitats.
(Jan 1, 2010 to Feb 8, 2012).
Disclosed in part 2,900
A-2012-00433 All briefing notes to health Minister about Nutrition North Canada.
(May 1, 2010 to Jun 13, 2012).
Disclosed in part 265
A-2012-00825 Briefing notes prepared for the Minister, the Minister's staff and Health Canada officials related to the Food Mail Program and/or Nutrition North Canada.
(Nov 1, 2008 to Aug 10, 2012).
Disclosed in part 265
A-2012-01583 All emails, correspondence, communications and all drafts prepared in response to question 1054 which was tabled in the House of Commons on January 28, 2013. All disclosed 235
A-2013-00342 Information regarding Maria'S Swedish Bitters, Alcohol Free, Natural Product Number (NPN) 80010605 by Flora Manufacturing & Distributing Ltd. Disclosed in part 170
A-2013-00716 Minister's briefing notes and reports on Manganese in drinking water.
(Jan 1 2010 to Dec 31, 2013).
Disclosed in part 439
A-2013-00790 Documents concerning advertising methods for tobacco packaging.
(Jan 1, 1995 to Dec 31, 2013).
Disclosed in part 1,689
A-2013-00931 Documents given to the Minister of Health regarding the October 3, 2013 announcement on closing loopholes in illicit drug prescription. Disclosed in part 6
A-2013-00963 Adverse Reaction Report (AER). Report numbers: 000534909, 000534594, 000530805, 000530823, 000530833, 000536409. Disclosed in part 15
A-2013-00967 List of all the federal buildings tested and the results of all the radon levels measured, including which buildings tested with radon levels above 200 Bq/m3. Disclosed in part 4,000
A-2013-00996 Product Safety Laboratory Functional Review, as per Merx Solicitation # 1000142255B. No records exist 0
A-2013-01082 Documents relating to Medical Grow Operation Application(s).
(Dec 6, 2011 to Dec 5, 2013).
Disclosed in part 43
A-2013-01084 Actual volume value of business received (Agency Nursing Service Activity Report) by Venture Healthcare Inc. under contract number H3551-112960/003/WPG and all amendments.
(Oct 31, 2012 to Oct 31, 2013).
All disclosed 5
A-2013-01085 Actual volume value of business (Agency Nursing Service Activity Report) received by Pedabun 35 Nursing Inc., Canadian Health Care Agency Ltd. In Joint Venture under contract number H3551-112960/001/WPG and all amendments.
(Oct 31, 2012 to Oct 31, 2013).
All disclosed 6
A-2013-01177 Information regarding Lypo-Spheric Vitamin C, Natural Product Number (NPN) 80045862 by LivOn Laboratories Inc. Disclosed in part 56
A-2013-01180 Documents related to an entry in the Public Accounts of Canada, 2012-13 that reads: Fraudulent claim for contribution (2 cases) in the amount of $115,926. Disclosed in part 31
A-2013-01245 Information regarding the medical device ULTRALIEVE PRO – PERSONAL, ULTRASOUND TREATMENT and ULTRALIEVE-ULTRASOUND THERAPY, License number 85372. Disclosed in part 107
A-2013-01296 Guiding criteria or evidence used to make the determination as to which program or service received a financial reduction under the Strategic and Operating Review. Disclosed in part 2
A-2013-01306 Briefing notes and all other communication regarding the report: Health Canada Library Services: Information, Risk and Analysis + Recommendations Report.
(Feb 17, 2013 to Apr 30, 2013).
Disclosed in part 283
A-2013-01310 List of each individual and corporation that has submitted an application to become a licensed producer under the new Marihuana for Medical Purposes Regulations and status of application Disclosed in part 15
A-2013-01354 Adverse Reaction Report (AER) for Synthroid. Report numbers: 000542937, 000556377. Disclosed in part 4
A-2013-01409 Adverse Reaction Report (AER) for Nasacort AQ (triamcinolone acetonide). Report number: 000118610. Disclosed in part 1
A-2013-01411 Adverse Reaction Report (AER) for Taxotere (docetaxel). Report number: E2B_00015580. Disclosed in part 93
A-2013-01420 Adverse Reaction Report (AER). Report numbers: 000545882, 000538899, E2B_00025454. Disclosed in part 34
A-2013-01423 Adverse Reaction Report (AER) for SPIRIVA. Report number: 000326082. Disclosed in part 1
A-2013-01424 Adverse Reaction Report (AER) for BIAXIN. Report number: 000544747. Disclosed in part 2
A-2013-01451 Adverse Reaction Report (AER) for Azithromycin. Report number: 000502050. Disclosed in part 2
A-2013-01452 All correspondence related to the 505(b)(2) application that may exist with Health Canada No records exist 0
A-2013-01455 A list from SAP, indicating the financial value of each award given to recipients in 2009 and 2010, the section of the department and the total value for each Directorate. Disclosed in part 31
A-2013-01458 All correspondence related to media requests for an interview with the Minister of Health.
(Jan 6, 2014 to Feb 3, 2014).
Disclosed in part 21
A-2013-01491 Documents on implementing and meeting the new medical marihuana supply system and Marihuana for Medical Purposes Regulations rules given that;
  • insufficient approved suppliers will be in place in the short term,
  • some medical users will not use official suppliers given quality and price,
  • public is not all behind wanting new neighbourhood official suppliers,
  • some municipalities will refuse to have such suppliers in their jurisdictions,
  • new suppliers will not all be able to handle increasing growth of users,
  • estimated revenues projected could be miscalculated and the overall business model may cause some suppliers financial difficulties,
  • users' personal lives could become more tracked and disrupted.
(Jan 1, 2013 to Mar 24, 2014).
No records exist 0
A-2013-01495 Information pertaining to losses and thefts reports for the product Hydromorph Contin.
(Aug 1, 2013 to Dec 31, 2013).
All disclosed 6
A-2013-01496 Information pertaining to losses and thefts reports for the product Biphentin.
(Aug 1, 2013 to Dec 31, 2013).
All disclosed 3
A-2013-01497 Information pertaining to losses and thefts reports for the product BuTrans.
(Aug 1, 2013 to Dec 31, 2013).
All disclosed 2
A-2013-01498 Information pertaining to losses and thefts reports for the product Codeine Contin.
(Aug 1, 2013 to Dec 31, 2013).
All disclosed 3
A-2013-01499 Information pertaining to losses and thefts reports for the product Dilaudid.
(Aug 1, 2013 to Dec 31, 2013).
All disclosed 4
A-2013-01500 Information pertaining to losses and thefts reports for the product MS Contin.
(Aug 1, 2013 to Dec 31, 2013).
All disclosed 3
A-2013-01501 Information pertaining to losses and thefts reports for the product Oxycontin. (Aug 1, 2013 to Dec 31, 2013). All disclosed 2
A-2013-01502 Information pertaining to losses and thefts reports for the product OxyNEO.
(Aug 1, 2013 to Dec 31, 2013).
All disclosed 5
A-2013-01504 Information pertaining to losses and thefts reports for all narcotics.
(Jan 1, 2011 to Dec 31, 2013).
All disclosed 28
A-2013-01505 Information pertaining to losses and thefts reports for the product Targin.
(Aug 1, 2013 to Dec 31, 2013).
All disclosed 2
A-2013-01506 Information pertaining to losses and thefts reports for the product Oxycodone.
(Aug 1, 2013 to Dec 31, 2013).
All disclosed 2
A-2013-01525 Documents between Hydro One and Health Canada in regards to the switchyard at the Ashfield Switching Station. No records exist 0
A-2013-01541 All documents relating to the request and supplementary execution of abortion in the city of Windsor, Ontario, Canada. No records exist 0
A-2013-01545 Adverse Reaction Report (AER) for Taro-Terconazole cream. Report number: 000544405. Disclosed in part 2